Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Breast Neoplasms 6 Neuroendocrine Tumors 5 Neoplasm Metastasis 3 Carcinoma, Renal Cell 3 Tuberous Sclerosis 2 Triple Negative Breast Neoplasms 2 Recurrence 2 Glioma 2 Endometrial Neoplasms 2 Adenoma, Islet Cell 2 von Hippel-Lindau Disease 1 Vascular Malformations 1 Unilateral Breast Neoplasms 1 Thymus Neoplasms 1 Seizures 1 Sarcoma, Kaposi 1 Sarcoma 1 Nevus 1 Myelodysplastic Syndromes 1 Multiple Endocrine Neoplasia Type 1 1 Metastatic Digestive System Neuroendocrine Tumor G1 1 Meningioma 1 Lymphangioma 1 Liposarcoma 1 Leukemia, Myeloid, Acute 1 Leiomyosarcoma 1 Kidney Neoplasms 1 Hemangioma 1 Hemangioendothelioma 1 Hamartoma Syndrome, Multiple 1

Interventions

pembrolizumab 1 fludarabine 1 Everolimus 1 Cyclophosphamide 1 177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Thymus Neoplasms × Everolimus × 90 days × Clear all

NCT05918302 2026-05-12

LEVEL

Grupo Espanol de Tumores Neuroendocrinos

Phase 3 Recruiting

Thymus Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡